Valaciclovir Mylan

Quick links

Choose a section

Quick links to important sections

Advertisements

Valaciclovir Mylan

Advertisements

Overview of Valaciclovir Mylan

Property Description
Active ingredient Valacyclovir Hydrochloride (Valaciclovir)
Form Film-coated tablets
Pharmacological class Antiviral, Purine Nucleoside Analogue
Common use Counteracting infections caused by herpes viruses
Origin Synthetic Prodrug (L-valine ester of Aciclovir)

What Type of Medicine is Valaciclovir Mylan?

Valaciclovir Mylan is a prescription-only, synthetic antiviral medicine belonging to the purine nucleoside analogue class, typically supplied as film-coated tablets for oral administration. Manufactured by Mylan Pharmaceuticals, this product is a generic medicine containing the active ingredient Valacyclovir Hydrochloride. It is used systemically to manage infections caused by the herpes family of viruses, such as Herpes Simplex Virus and Varicella Zoster Virus.

Valaciclovir's Unique Identity: Why is it a Prodrug?

Valaciclovir is chemically classified as a prodrug, meaning the molecule is initially inactive and requires the body’s metabolic enzymes to convert it into its effective antiviral substance, Aciclovir. This synthetic design, which links the L-valine amino acid to the Aciclovir molecule, enables significantly better oral absorption compared to Aciclovir itself. This formulation is designed to result in higher bioavailability of the active compound. This means the prodrug ensures a potent and reliable concentration of the virus-fighting compound reaches the bloodstream.

General Benefit: What is the Purpose of this Antiviral?

The primary purpose of Valaciclovir is to limit the spread of viral infection by inhibiting the capacity of targeted herpes viruses to replicate within the host's cells. The active metabolite, Aciclovir, achieves this by mimicking a natural guanosine nucleoside. Once incorporated into the virus’s developing genetic material, it causes DNA chain termination, effectively blocking the viral DNA polymerase. This highly targeted mechanism forms the foundation of the drug's therapeutic action against viral activity.

Advertisements

What side effects are possible with Valaciclovir Mylan?

Possible Side Effects and Safety Information

The safety profile of Valaciclovir Mylan is officially classified by frequency and impact on body systems, based on regulatory documentation from authorities like the EMA and FDA. These classifications organize the documented adverse reactions and safety statements without offering instruction or clinical advice.

Frequency-Classified Adverse Reactions

The most commonly reported effect, categorized as Very Common (ge 1/10), is Headache. Effects considered Common (ge 1/100 to <1/10) include Nausea and Abdominal pain in adults. Reactions are grouped by System-Organ-Classes (SOC), with effects noted in the Gastrointestinal Disorders and Nervous System Disorders being frequently documented.


Documented Safety Concerns

The official label identifies rare, serious adverse reactions. These include Acute Renal Failure and severe Central Nervous System (CNS) effects such as Encephalopathy and Seizures. In specific immunocompromised patients (e.g., organ transplant recipients) receiving high doses, Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS) have been documented.

These CNS effects are generally noted in regulatory documents as reversible upon cessation of treatment.

Population-Specific Notes and Safety Constraints

Official safety information states that Older adults (geriatric patients) and individuals with renal impairment are at an increased risk for CNS adverse reactions and acute renal failure. A critical safety constraint is the requirement for adequate hydration to be maintained by all patients during therapy to prevent the precipitation of the active metabolite within the renal tubules.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documentation defines the overdose profile of Valaciclovir Mylan primarily based on the accumulation of its active metabolite, Aciclovir, which can lead to serious toxicity. Immediate medical attention must be sought in the event of a suspected or known overdose; contact emergency services or a Poison Control center, as mandated by official labeling.

Documented Overdose Manifestations

Official prescribing information lists both gastrointestinal and severe central nervous system (CNS) effects following overdosage. Nausea, vomiting, confusion, hallucinations, agitation, and lethargy are documented presentations. More severe outcomes include seizures, coma, and acute renal failure (ARF).

Required Emergency Actions and Management

  • Emergency Response: Immediate medical attention is required. This is the non-negotiable instruction stated in governmental labels when an overdose is suspected.
  • Management: Management is symptomatic and supportive. No specific antidote is known. In severe, symptomatic cases, haemodialysis can be considered, as it significantly accelerates the elimination of the active substance from the blood.

Population-Specific Risk

Elderly patients and individuals with pre-existing renal impairment are documented to be at a heightened risk for severe neurotoxicity and ARF, often due to the accumulation of the drug metabolite.

Advertisements

Therapeutic Uses of Valaciclovir Mylan

Quick Facts

  • Condition Areas: Herpes simplex virus (HSV) and Varicella zoster virus (VZV).
  • Key Indications: Treatment of cold sores (herpes labialis) and shingles (herpes zoster).
  • Other Uses: Management and suppression of genital herpes outbreaks.

What Valaciclovir Mylan Treats: Main Uses and Benefits

Valaciclovir Mylan is an authorized treatment intended for managing infections caused by certain herpes viruses. It is primarily used to address the Varicella zoster virus (VZV), which is the source of shingles (herpes zoster). Timely use of this medication may help reduce discomfort and support the healing of the lesions associated with this condition.

The medication is also a therapeutic option for infections involving the Herpes simplex virus (HSV). This includes the treatment of cold sores (herpes labialis) in adults and adolescents. For adults, it is also indicated for the management of initial and recurrent episodes of genital herpes, as well as for chronic suppressive therapy to help reduce the frequency of outbreaks. In certain patient populations, this medication may also be used to address the risk of cytomegalovirus (CMV) infection following solid organ transplantation. Healthcare providers determine the appropriate course of treatment based on the specific infection and individual patient factors.

Regulatory References

  1. NIH MedlinePlus guidance on valacyclovir
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Valaciclovir Mylan?

This medication is subject to official regulatory rules that define the eligible population. The primary absolute contraindication is a known hypersensitivity or allergy to valaciclovir, its active metabolite aciclovir, or any other component in the formulation.

Eligibility Classification Affected Population Requirement/Status
Contraindicated Patients with known allergy to valaciclovir or aciclovir Must not use
Use with Caution/Restricted Patients with impaired renal function or the elderly Requires dosage adjustment and caution due to risk of accumulation
Conditional Use Pregnant or Breastfeeding patients Permitted only if the potential benefit justifies the possible risk to the fetus/infant
Limited Use Immunocompromised patients (non-HIV) Safety and efficacy not established for most indications

Age-Related Eligibility is indication-specific. Use is generally authorized for adults. For children, the use of valaciclovir is established for cold sores in adolescents ge 12 years and for chickenpox in immunocompetent patients aged 2 to <18 years. Use is not established for treating shingles or genital herpes in patients under 18 years of age. Patients with kidney problems must also ensure adequate fluid intake.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Valaciclovir’s interaction profile is primarily related to the renal elimination of its active metabolite, acyclovir, which is removed from the body through both glomerular filtration and active renal tubular secretion.

Interacting Product Category Example Medicines Listed in Regulatory Documents Interaction Constraint and Mechanism
Nephrotoxic Drugs Aminoglycosides, Ciclosporin, Tacrolimus Increased risk of renal dysfunction, including acute renal failure. Co-administration requires caution and careful monitoring of kidney function.
Inhibitors of Active Renal Tubular Secretion Cimetidine, Probenecid These medicines competitively inhibit the tubular secretion of acyclovir, increasing the systemic concentration (AUC) of acyclovir.

Co-administration with probenecid (a gout medicine) or cimetidine (a stomach ulcer medicine) reduces the renal clearance of acyclovir, leading to higher levels of the active drug in the blood. In patients with normal kidney function, this increase is typically not considered clinically significant by regulatory bodies, and a dose adjustment is generally not required. However, the risk of serious adverse effects is heightened when Valaciclovir is co-administered with other medicines that are known to impair kidney function (nephrotoxic drugs) or in patient populations with already reduced kidney function, such as the elderly. The combination with such agents requires medical consultation and close monitoring.

Advertisements

Mechanism of Action

Selective Activation by Viral Thymidine Kinase

Valaciclovir functions as a prodrug, requiring conversion to Aciclovir by human hydrolase enzymes. The subsequent activation relies entirely on the virus-specific enzyme Viral Thymidine Kinase (vTK), which is primarily present inside infected cells. The vTK enzyme mediates the initial phosphorylation of Aciclovir, leading to the eventual formation of the active antiviral compound, Aciclovir Triphosphate. This highly selective activation process facilitates the compound's concentration at the site of viral activity.

Molecular Inhibition of Viral DNA Synthesis

The active compound, Aciclovir Triphosphate, acts as a competitive inhibitor of the essential enzyme Viral DNA Polymerase. The molecule structurally mimics a natural nucleoside, allowing the DNA Polymerase to incorporate it into the nascent viral DNA chain. Once incorporated, the molecule causes immediate and permanent DNA chain termination.

Functional Consequence: Arrest of Viral Proliferation

By halting the virus's ability to synthesize its genetic material, this mechanism directly prevents the production of new viral particles within the host cell. This resulting physiological effect restricts the viral replication cycle, thereby limiting the capacity of the infection to spread throughout the surrounding tissues. The mechanism is functionally constrained by the presence of viral strains that are deficient in the activating enzyme vTK.

Advertisements

Dosage and Administration Information

Valaciclovir Mylan is intended exclusively for oral administration as a film-coated tablet and should be swallowed whole with fluid. The medicine may be taken without regard to meals and does not require specific timing relative to food intake. Dosage and frequency are indication-specific, meaning the required regimen varies entirely based on the condition being managed.

For instance, the regimen for Herpes Zoster (shingles) is typically 1 gram three times daily for a fixed 7-day duration, while the usage pattern for cold sores involves a 2-gram dose twice daily for only one day, taken 12 hours apart. For complex prophylactic use, such as preventing Cytomegalovirus (CMV) infection, the dose can be as high as 2 grams four times daily. Treatment for acute episodes must follow the official principle of timely initiation, beginning at the earliest sign or symptom of the outbreak.

A mandatory dose reduction is required for all patients with impaired renal function (kidney disease), with the correct schedule determined by their measured Creatinine Clearance. Patients must ensure adequate hydration throughout the treatment course. If a dose is missed, it should be taken immediately, but double doses are explicitly prohibited to make up for a forgotten dose.

Advertisements

Recent Clinical Evidence

Valaciclovir Mylan: Recent Clinical Evidence

Clinical evidence for Valaciclovir Mylan centers on its established use in managing infections caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV), which include cold sores, genital herpes, and shingles.

Recent research has explored the drug's role in therapeutic strategies, focusing on convenience, long-term safety, and potential use in special populations.


Efficacy and Comparative Studies

Studies have consistently examined the effects of valaciclovir against various viral manifestations:

  • Shingles (Herpes Zoster): Randomized clinical trials (RCTs) have compared valaciclovir with its precursor, acyclovir, in immunocompetent adults. These studies indicated that valaciclovir was associated with a greater reduction in the duration of pain linked to shingles (zoster-associated pain) compared to acyclovir.
  • Cold Sores (Herpes Labialis): Research has supported the use of short-duration, high-dose regimens for treating recurrent cold sores, demonstrating that this dosing schedule was associated with a reduction in the median duration of the episode and the time to lesion healing compared to placebo.
  • Genital Herpes: Studies have investigated valaciclovir in both episodic treatment (treating active outbreaks) and suppressive therapy (reducing recurrence risk). When used for suppression, evidence suggests valaciclovir is associated with a reduction in the risk of viral transmission to sexual partners.

Safety and Special Populations

Long-term safety data, sometimes extending over multiple years, have been collected, particularly for individuals using valaciclovir for the suppression of recurrent genital herpes. The safety profiles of valaciclovir and acyclovir in these long-term studies have been reported as similar. Data collection across clinical trials has identified the most frequently reported adverse events as gastrointestinal issues and headaches, generally documented as mild or moderate in severity.

In older adults and patients with impaired kidney function, research emphasizes that the drug's elimination is affected, which may necessitate careful consideration of dose adjustments.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Valaciclovir Mylan (FAQ)


Q: Is Valaciclovir Mylan the same as Valtrex?

Valaciclovir Mylan is a generic version of the medicine containing the active ingredient valaciclovir hydrochloride. Valtrex is the common brand name that contains the exact same active ingredient. Official information confirms they are pharmaceutically equivalent.


Q: Is it common to feel nausea when starting Valaciclovir Mylan?

According to the official safety profile, nausea is classified as a common side effect of this medicine. This means it is documented to occur in a common range (ge 1/100 to <1/10) of patients who use Valaciclovir Mylan.


Q: Can Valaciclovir Mylan be crushed or split if the tablet is too large?

Official prescribing information describes Valaciclovir Mylan as a film-coated tablet intended for oral administration. The instructions state that the tablet should be swallowed whole with fluid.


Q: Is it possible to become resistant to Valaciclovir Mylan over time?

Official documents describe that viral resistance has been reported, especially in immunocompromised patients. This often involves viral strains that are deficient in the enzyme needed for the drug to become active. The possibility of resistance is considered when a poor clinical response is observed during therapy.


Q: How quickly should I expect to see an effect from Valaciclovir Mylan?

Studies have examined the time it takes to see an effect when treatment is started early. According to clinical data, for recurrent cold sores, treatment was associated with about one day less duration compared to placebo. For recurrent genital herpes, official information indicates a median time of three to four days for pain to stop and lesions to heal.


Q: Does Valaciclovir Mylan start working immediately after I take it?

As a prodrug, Valaciclovir is rapidly absorbed from the gut and converted by the body’s enzymes into the active antiviral compound, aciclovir. This active compound begins its therapeutic action, which is designed to help limit viral replication.


Q: Does Valaciclovir Mylan stay in your system for a long time?

The active substance, aciclovir, has a short half-life of about 2.5 to 3.3 hours in adults with normal kidney function. This means the majority of the substance is estimated to be eliminated from the body within about one day after the last dose.


Q: Can Valaciclovir Mylan cause dizziness or drowsiness?

Yes, dizziness is classified in official safety documents as a common side effect of the medicine. Feeling very drowsy, a more significant nervous system effect, is also documented in the less common category.


Q: Does Valaciclovir Mylan affect my ability to drive?

The medicine can cause side effects, such as dizziness or drowsiness, that may affect a patient’s ability to drive or operate machinery. Official patient information indicates that driving or operating machinery should be avoided if a person experiences side effects that may affect their ability, such as dizziness or drowsiness.


Q: Is Valaciclovir Mylan effective against all types of herpes viruses?

Valaciclovir is indicated for treating infections caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV). Official documents also list its use for the prevention of infection with cytomegalovirus (CMV) following certain organ transplants.


Q: What kind of infections does Valaciclovir Mylan treat besides herpes?

Valaciclovir is an antiviral primarily targeting the herpes family of viruses, including Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV). It is also used to prevent infection caused by Cytomegalovirus (CMV) following certain organ transplants.


Q: Does taking Valaciclovir Mylan mean the infection is cured?

Valaciclovir Mylan is an antiviral medicine that works by inhibiting the capacity of the virus to replicate. According to official health information, it is not considered a cure for herpes infections, as the viruses remain in the body between outbreaks.


Q: Does Valaciclovir Mylan prevent the spread of the virus?

The medicine is indicated for the reduction of transmission of genital herpes in certain adult couples. Official documents state that suppressive therapy with Valaciclovir significantly reduces the risk of transmission of genital herpes.


Q: Why is this drug typically prescribed for herpes zoster (shingles)?

Valaciclovir is an approved treatment for Herpes Zoster (shingles). Clinical research indicated that it was associated with a greater reduction in the duration of pain linked to shingles compared to its precursor, aciclovir.


Q: Why do some people need a higher dose than others?

The dose of Valaciclovir Mylan is tailored to the specific condition being treated, which is known as indication-specific dosing. Adjustments are also required for individuals with impaired kidney function, and immunocompromised patients may also require a higher dose or longer duration for certain conditions.


Q: Is long-term use of Valaciclovir Mylan safe?

For suppressive therapy against recurrent outbreaks, the official prescribing information states that the efficacy and safety of Valaciclovir Mylan are not established beyond a period of one year in immunocompetent patients.


Q: Has Valaciclovir Mylan been studied in immunocompromised patients?

Efficacy and safety are not established for most immunocompromised patients. However, exceptions are noted in regulatory documents, such as for the suppressive treatment of genital herpes in HIV-1-infected adults who meet specific clinical criteria.


Q: Can Valaciclovir Mylan affect liver function?

Official safety information documents that reversible abnormalities, such as increases in liver function tests and liver enzymes, have been reported in patients taking this medicine.


Q: Are there any common skin side effects from Valaciclovir Mylan?

Yes, official safety documents list several common skin side effects. These include rash, itching, and skin reaction after exposure to sunlight (photosensitivity).


Q: Does Valaciclovir Mylan cause hair loss?

Hair loss or thinning of the hair has been reported in post-marketing surveillance. This is not listed among the common or very common side effects in clinical trials, and the exact incidence of this side effect is not officially known.


Q: Does Valaciclovir Mylan cause weight gain or loss?

Weight gain or weight loss are not listed as documented side effects of the medicine based on data from clinical studies.


Q: What happens if I take Valaciclovir Mylan past the expiration date?

Regulatory patient information advises against using the tablets after the expiry date has passed. Official guidance notes that the medicine may not work as effectively if taken beyond this date.


Q: Can I take ibuprofen or paracetamol while using Valaciclovir Mylan?

Official warnings describe that caution is required when Valaciclovir is combined with other medicines known to impair kidney function, such as ibuprofen. Combining them can increase the risk of renal dysfunction. No specific warning is generally given for paracetamol.


Q: Does Valaciclovir Mylan interact with alcohol?

Official documents do not explicitly list an interaction with alcohol. However, since the medicine is associated with risks of kidney problems and nervous system effects, due to the potential for nervous system effects, caution related to alcohol consumption is often suggested.


Q: Are there any dietary restrictions when taking this medicine?

Official prescribing information states the medicine may be taken without regard to meals. There are no specific dietary restrictions listed in regulatory warnings or patient leaflets.


Q: Can people with diabetes use Valaciclovir Mylan?

Official regulatory documents do not list diabetes as a specific contraindication or a condition that requires a dose adjustment for the use of Valaciclovir Mylan. The primary restrictions relate to known allergies, impaired kidney function, and specific age groups.


Q: Is Valaciclovir Mylan safe for people with heart conditions?

Official regulatory documents do not list a specific contraindication or restriction for patients with heart conditions. The primary warnings and contraindications relate to kidney function, liver issues, and known hypersensitivity.


Q: Is there any research on using Valaciclovir Mylan for chronic fatigue?

Official regulatory documents indicate that Valaciclovir Mylan is restricted to treating infections caused by the herpes family of viruses, such as HSV and VZV. Use for chronic fatigue syndrome or similar conditions is not described in these documents.

Advertisements

How should Valaciclovir Mylan be stored and disposed of?

Valaciclovir Mylan tablets must be stored according to regulatory requirements to preserve product stability.


Storage Conditions

Requirement Official Instruction
Temperature Store at room temperature, typically below 30°C (86°F). Do not freeze.
Protection Protect from light and moisture.
Packaging Keep in the original container and ensure it is tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Do not use the tablets after the expiry date. Unused or expired Valaciclovir Mylan must not be disposed of in household garbage or flushed down the toilet (wastewater). For proper pharmaceutical waste handling, return the medication to a pharmacist or follow local government-approved collection guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valaciclovir Mylan found in:

A-Z Index: